Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.
Case
-
Reference no. 9-501-061
Subject category: Marketing
Authors: Robert J Dolan
Published by: Harvard Business Publishing
Originally published in: 2001
Version: 9 January 2001
Length: 14 pages
Data source: Field research

Abstract

Abgenix has a unique method for generating antibodies useful in treating a number of diseases, including cancer. In early 2000, the company's cancer has performed very well in animal testing and is moving to early stage human testing. Abgenix must decide whether to sell the product development program to a large pharmaceutical company or to enter into a joint venture to push the product ahead.
Location:
Industry:
Size:
USD12 million revenues, 150 employees
Other setting(s):
2000

About

Abstract

Abgenix has a unique method for generating antibodies useful in treating a number of diseases, including cancer. In early 2000, the company's cancer has performed very well in animal testing and is moving to early stage human testing. Abgenix must decide whether to sell the product development program to a large pharmaceutical company or to enter into a joint venture to push the product ahead.

Settings

Location:
Industry:
Size:
USD12 million revenues, 150 employees
Other setting(s):
2000

Related